Testosterone results are only useful when the sample is taken under the right conditions and interpreted as part of a hormonal pattern. Timing, fasting, illness, SHBG and repeat testing can change the conclusion.
A testosterone blood test is easy to order and easy to misinterpret. The number changes across the day, after food, during illness and between laboratory methods. Sex hormone-binding globulin can make total testosterone look lower or higher than the testosterone available to tissues. A single low result may not stay low when repeated.
Proper testosterone testing is a process, not a score. The first test asks whether deficiency is plausible. A second correctly timed measurement checks whether the result is persistent. Related hormones help show where the problem may be. The clinical history determines whether the pattern explains the symptoms and what should happen next.
For the biochemical assessment of suspected male hypogonadism:
One isolated result should not decide whether a man starts TRT.
Testing is most useful when symptoms or signs raise a reasonable suspicion of deficiency. These include reduced libido, fewer spontaneous erections, erectile dysfunction accompanied by other features, reduced body hair, small testes, infertility, gynaecomastia, hot flushes, low-trauma fracture or a combination of physical and psychological symptoms.
Testing may also be appropriate in selected conditions associated with hypogonadism, guided by a clinician. The European Association of Urology lists pituitary disease, testicular disorders, certain medicines, anabolic-steroid exposure, obesity, chronic disease and metabolic conditions among relevant causes or associations.
Routine population screening and symptom-quiz diagnosis are different propositions. A vague symptom such as tiredness has many causes. Testing may still be reasonable, but the result should sit within a broader assessment of sleep, mood, thyroid function, anaemia, metabolic health, nutrition and medication.
In men with a conventional sleep pattern, total testosterone should be measured in the morning. The joint UK position statement advises a morning, fasting sample and states that samples taken later than 11am should not be used to diagnose male hypogonadism. The EAU specifies a morning window of 7am to 10am.
The reason is biological variation. Testosterone secretion follows a daily rhythm and is usually highest after sleep and earlier in the waking day, especially in younger men. A late sample can make a normal level look low.
Night-shift workers and men with disrupted sleep do not fit neatly into a clock-time rule. They should tell the clinician and laboratory about their sleep-wake pattern. Timing may need to be based on the biological morning after adequate sleep, but interpretation is less standardised and should follow the clinical protocol rather than an improvised home rule.
Yes, when the test is being used to diagnose testosterone deficiency under the UK joint position statement. Food intake can lower measured testosterone, so a non-fasting result may create a false impression of deficiency. Follow the laboratory's fasting instructions, which normally permit plain water.
Do not stop prescription medicines in order to “improve” the result. Record what you take and let the clinician decide whether a medicine affects testosterone or the assay. That includes opioids, glucocorticoids, testosterone, anabolic steroids, selective oestrogen receptor modulators, hCG, supplements and medicines affecting the pituitary or liver.
Acute illness can temporarily suppress testosterone. A test taken during a fever, significant infection, hospital admission or recovery from major illness may not represent the usual baseline. The UK position statement says measurements during acute illness should not be used to diagnose hypogonadism.
Other short-term factors can add noise, including marked sleep deprivation, extreme training, severe calorie restriction and a recent change in hormone or anabolic-steroid use. Do not manipulate normal life simply to obtain a higher result; provide the context so the clinician can decide whether to test now or repeat later.
Testosterone varies within the same person. Biological rhythm, food, sleep, illness, assay variation and random fluctuation can all move a result. Repeating the measurement on a different day tests whether the finding is consistent.
Both measurements should be collected under comparable, appropriate conditions. Repeating a late-afternoon, non-fasting result does not correct the problem. The EAU recommends at least two separate measurements when total testosterone is below 12 nmol/L and before testosterone therapy.
The repeat is a diagnostic safeguard, not administrative delay. TRT suppresses natural testosterone signalling and sperm production and requires ongoing monitoring. That is too consequential a decision to base on one noisy measurement.
There is no single universal panel. A staged pathway often begins with total testosterone and adds tests according to the result and clinical question.
Total testosterone includes testosterone bound tightly to SHBG, testosterone bound more loosely to albumin and the small unbound fraction. It is the standard first biochemical test because it is widely available and better standardised than most direct free-testosterone assays.
The result is usually reported in nanomoles per litre in the UK. US websites commonly use nanograms per decilitre, which can cause confusion when readers compare thresholds without converting units or considering different guidance.
SHBG is a protein that binds testosterone. A high SHBG can make total testosterone look reassuring while calculated free testosterone is low. A low SHBG can make total testosterone look low even when the biologically available fraction is adequate.
SHBG may be altered by age, obesity, insulin resistance, thyroid disease, liver disease, certain medicines and other conditions. It is particularly useful when total testosterone is borderline or the clinical picture and total result do not match.
Albumin is another testosterone-binding protein. Total testosterone, SHBG and albumin can be used to calculate an estimate of free testosterone.
The Society for Endocrinology position statement makes an important distinction:
Direct free-testosterone immunoassays are often inaccurate. Equilibrium dialysis is the reference method but is not routinely available in UK practice. A result labelled simply “free testosterone” should therefore be interpreted with the laboratory method in mind.
LH and FSH show how strongly the pituitary is signalling the testes.
| Pattern | Possible interpretation |
|---|---|
| Low testosterone with raised LH, often raised FSH | Primary hypogonadism: the testes are not responding adequately |
| Low testosterone with low or inappropriately normal LH/FSH | Secondary hypogonadism: hypothalamic or pituitary signalling is inadequate, or the axis is functionally suppressed |
| Low testosterone with mixed or borderline gonadotrophins | Requires clinical interpretation; chronic illness, obesity, medicines and combined causes may blur the pattern |
FSH is also relevant to sperm production, but a hormone panel does not replace semen analysis when fertility is the question.
Raised prolactin can suppress gonadotrophin signalling, reduce testosterone and contribute to low libido or erectile dysfunction. It is particularly relevant when secondary hypogonadism is suspected, sexual desire is low or symptoms suggest a pituitary problem.
A raised result may need repeating under controlled conditions and investigating for medicines, stress, thyroid disease, macroprolactin or pituitary pathology. The required response depends on the value and symptoms.
Men produce oestradiol mainly by converting testosterone through the aromatase enzyme. Oestradiol is important for bone and sexual health. Testing may be appropriate in selected situations, such as gynaecomastia, certain fertility assessments or treatment monitoring, but it is not automatically required for every initial low-testosterone screen.
A broader assessment might include full blood count, thyroid function, glucose or HbA1c, liver and kidney markers, ferritin, lipids or other pituitary hormones. These do not diagnose low testosterone directly; they investigate alternative causes, associated conditions or treatment safety.
Before TRT, haematocrit, prostate risk and cardiovascular health require specific assessment. PSA testing depends on age, risk, symptoms and the shared decision with the clinician; it is not a universal add-on without context.
The UK Society for Endocrinology and laboratory-medicine position statement provides the following framework for symptomatic men tested correctly:
| Morning, fasting total testosterone | What it generally means |
|---|---|
| Below 8 nmol/L twice | Hypogonadism is likely; classify the cause and assess treatment suitability |
| 8–12 nmol/L | Can occur in eugonadal or hypogonadal men; interpret symptoms, SHBG and calculated free testosterone where indicated |
| Above 12 nmol/L | Not usually consistent with hypogonadism; one valid result above 12 nmol/L will usually exclude it |
The EAU uses below 12 nmol/L, repeated on at least two occasions in a symptomatic man, as a diagnostic threshold for late-onset hypogonadism. The greatest treatment benefits are generally seen in men with more marked biochemical deficiency.
These frameworks are not contradictory when used properly. Below 8 nmol/L is a clearer biochemical signal; 8–12 nmol/L is the zone where context matters most. A clinic that converts the entire borderline zone into automatic treatment is not applying the guidance.
For testosterone, an approximate conversion is:
This makes 8 nmol/L about 231 ng/dL and 12 nmol/L about 346 ng/dL. Conversion does not make US and UK diagnostic rules interchangeable. Assays, populations, guidance and clinical pathways differ.
A unit converter can help compare results reported in different formats, but it changes units rather than diagnosing a condition.
| Factor | Possible effect or problem |
|---|---|
| Late sampling | May read lower than a properly timed morning sample |
| Eating before the test | Can lower testosterone and complicate diagnostic interpretation |
| Acute illness | May temporarily suppress the hormonal axis |
| Poor or disrupted sleep | Can alter the daily rhythm and result |
| Obesity or insulin resistance | Often lowers SHBG and therefore total testosterone |
| Ageing, hyperthyroidism or some liver conditions | May raise SHBG and mask low calculated free testosterone |
| Opioids or glucocorticoids | Can suppress hypothalamic-pituitary signalling |
| Testosterone or anabolic steroids | Suppress natural LH, FSH and endogenous testosterone production |
| Assay or laboratory differences | Can shift results and reference ranges |
Document these factors so the result can be interpreted accurately.
Venous sampling is the established diagnostic route and allows enough material for a broader panel. Sample quality and laboratory handling remain important.
Capillary collection can make initial testing more accessible. Its suitability depends on the device, collection quality, analyte, transport conditions, laboratory validation and the clinical pathway. A home kit does not become diagnostic simply because it is convenient or processed by an accredited laboratory.
If an initial capillary result is low, borderline, unexpected or inconsistent with symptoms, confirmatory testing and clinical review are appropriate. Before testing, check which sample type is accepted at each stage rather than relying on a generic “highly accurate” claim.
Salivary testosterone is used in some research settings, but it is not the standard UK diagnostic test for adult male hypogonadism. A consumer saliva result should not be used to start TRT.
A safe pathway should not jump straight from “low” to a prescription. It should:
If the repeated testosterone result is normal, the symptoms still deserve attention. The next step may be investigation of sleep apnoea, thyroid disease, anaemia, depression, medication effects, metabolic disease, under-fuelling or another cause.
Monitoring is formulation-specific and should be prescribed, not improvised. The clinician needs to know when the sample was taken in relation to the injection, gel application or other dose. A level without that timing can be misleading.
The EAU recommends monitoring testosterone and haematocrit at three, six and 12 months after starting treatment and annually thereafter, with closer checks in men at higher risk of raised haematocrit. PSA, symptoms, blood pressure and metabolic factors may also need monitoring based on age and risk.
The target is a physiological level with symptom benefit and acceptable safety—not the highest result a laboratory will report as “normal”.
Yes, but it becomes a monitoring test rather than a baseline diagnostic test. The correct timing depends on the formulation and dosing schedule, so follow the prescriber's instructions.
Low SHBG can produce that pattern, often in obesity or insulin resistance. It may argue against true androgen deficiency, but the clinician must review the assay, calculation, symptoms and wider health picture.
The symptoms remain valid. A normal testosterone result should redirect the assessment towards other causes rather than trigger treatment to push testosterone above the physiological range.
